Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update

Yimin Mao,Shiwu Ma,Chenghai Liu,Xiaoyan Liu,Minghua Su,Dongliang Li,Yiling Li,Gongying Chen,Jun Chen,Jinjun Chen,Jingmin Zhao,Xiaoyan Guo,Jieting Tang,Yuzheng Zhuge,Qing Xie,Wen Xie,Rongtao Lai,Dachuan Cai,Qingxian Cai,Yang Zhi,Xiaoyun Li,the Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association

DOI: https://doi.org/10.1007/s12072-023-10633-7

IF: 9.029

2024-02-26

Hepatology International

Abstract:Drug-induced liver injury (DILI) is an important adverse drug reaction that can lead to acute liver failure or even death in severe cases. Currently, the diagnosis of DILI still follows the strategy of exclusion. Therefore, a detailed history taking and a thorough and careful exclusion of other potential causes of liver injury is the key to correct diagnosis. This guideline was developed based on evidence-based medicine provided by the latest research advances and aims to provide professional guidance to clinicians on how to identify suspected DILI timely and standardize the diagnosis and management in clinical practice. Based on the clinical settings in China, the guideline also specifically focused on DILI in chronic liver disease, drug-induced viral hepatitis reactivation, common causing agents of DILI (herbal and dietary supplements, anti-tuberculosis drugs, and antineoplastic drugs), and signal of DILI in clinical trials and its assessment.

gastroenterology & hepatology

What problem does this paper attempt to address?

The paper primarily addresses the following issues:

1. **Purpose of Updating the Guidelines**: The paper aims to update the 2017 Chinese guidelines for the diagnosis and treatment of drug-induced liver injury (DILI) to reflect new advancements and evidence in the field of DILI in recent years.

2. **Key Focus Areas**: It particularly focuses on several aspects common in Chinese clinical practice, including DILI in patients with chronic liver disease, drug-induced reactivation of viral hepatitis, common drugs causing DILI (such as herbs and dietary supplements, anti-tuberculosis drugs, and anti-cancer drugs), and the detection and evaluation of DILI signals in clinical trials.

3. **Diagnosis and Management**: It provides professional guidance to help clinicians promptly identify suspected DILI cases and standardize the diagnosis and management processes of DILI.

4. **Global Perspective**: It takes into account the global trends in DILI research, especially the challenges brought by the increased use of herbal and alternative medicine in Asian and African countries, as well as new issues arising from the approved use of targeted therapies and immune checkpoint inhibitors (ICIs).

5. **Addressing Specific Issues**: It discusses chronic DILI, specific types of DILI phenotypes, DILI in the presence of underlying liver disease, drug-induced reactivation of viral hepatitis, and the detection and evaluation of DILI signals in clinical trials.

In summary, the main purpose of this paper is to provide the latest guidelines to help healthcare professionals better understand and manage various situations of drug-induced liver injury, particularly the specific challenges faced in China and other regions.